urea has been researched along with Cannabis Abuse in 3 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| "PF-04457845, a novel FAAH inhibitor, reduced cannabis withdrawal symptoms and cannabis use in men, and might represent an effective and safe approach for the treatment of cannabis use disorder." | 2.90 | Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. ( Bielen, K; Bluez, G; Cahill, J; Cortes-Briones, J; Creatura, G; D'Souza, DC; Deaso, E; Gupta, A; Gupta, S; Makriyannis, A; Morgan, PT; Radhakrishnan, R; Ranganathan, M; Sherif, MA; Skosnik, PD; Surti, T; Thurnauer, H, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nourbakhsh, M | 1 |
| Miller, A | 1 |
| Gofton, J | 1 |
| Jones, G | 1 |
| Adeagbo, B | 1 |
| D'Souza, DC | 1 |
| Cortes-Briones, J | 1 |
| Creatura, G | 1 |
| Bluez, G | 1 |
| Thurnauer, H | 1 |
| Deaso, E | 1 |
| Bielen, K | 1 |
| Surti, T | 1 |
| Radhakrishnan, R | 1 |
| Gupta, A | 1 |
| Gupta, S | 1 |
| Cahill, J | 1 |
| Sherif, MA | 1 |
| Makriyannis, A | 1 |
| Morgan, PT | 1 |
| Ranganathan, M | 1 |
| Skosnik, PD | 1 |
| Flores, Á | 1 |
| Maldonado, R | 1 |
| Berrendero, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FAAH-Inhibitor for Cannabis Dependence[NCT01618656] | Phase 2 | 70 participants (Actual) | Interventional | 2012-09-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"32-item checklist evaluating potential symptoms of cannabis withdrawal, lower values reflect lesser severity of withdrawal symptoms (lower scores represent a better outcome).~Min: 0 Max: 96" (NCT01618656)
Timeframe: The MWC was administered on Day 0, Day 1, Day 2, Day 3, and Day 4 (during the inpatient phase when withdrawal peaks) to assess change from baseline (Day 0). The scores from each time point and subject were calculated to report the mean score for each arm.
| Intervention | score on a scale (Mean) |
|---|---|
| PF-04457845 (4mg by Mouth Daily for 4 Weeks) | 6.04 |
| Placebo (Sugar Pill, by Mouth Daily for 4 Weeks) | 11 |
Polysomnography (PSG) is a comprehensive reading of biophysiological changes that occur during sleep, including identification of sleep stage. A mean and standard deviation of their data points during sleep stages were calculated to determine change from baseline to the end of study treatment. (NCT01618656)
Timeframe: Polysomnography was collected two nights prior to baseline visit, for three nights during study treatment and two nights after four weeks of study treatment. A mean was calculated to assess change from baseline (Day 0).
| Intervention | minutes (Mean) |
|---|---|
| PF-04457845 (4mg by Mouth Daily for 4 Weeks) | 89.56 |
| Placebo (Sugar Pill, by Mouth Daily for 4 Weeks) | 69.29 |
"Subject quantifies and reports frequency of cannabis use prior to study participation and during the 4 week period. Lower scores reflect less cannabis usage, while higher scores reflect more frequent usage.~Min: 0 Max: undeterminable, varies per patient and their usage." (NCT01618656)
Timeframe: Administered weekly for 4 weeks to assess change from baseline (Day 0). The scores from each time point and subject were calculated to report the mean score for each arm.
| Intervention | joints per day (Mean) |
|---|---|
| PF-04457845 (4mg by Mouth Daily for 4 Weeks) | 0.40 |
| Placebo (Sugar Pill, by Mouth Daily for 4 Weeks) | 1.27 |
Subjects provide urine samples to quantify levels of THC. (NCT01618656)
Timeframe: Samples obtained weekly for 4 weeks to assess change from baseline (Day 0). The results from each time point and subject were calculated to report the mean score for each arm.
| Intervention | ng/mL (Mean) |
|---|---|
| PF-04457845 (4mg by Mouth Daily for 4 Weeks) | 265.55 |
| Placebo (Sugar Pill, by Mouth Daily for 4 Weeks) | 657.92 |
1 trial available for urea and Cannabis Abuse
| Article | Year |
|---|---|
Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.
Topics: Adolescent; Adult; Amidohydrolases; Cannabis; Double-Blind Method; Humans; Male; Marijuana Abuse; Ma | 2019 |
2 other studies available for urea and Cannabis Abuse
| Article | Year |
|---|---|
Cannabinoid Hyperemesis Syndrome: Reports of Fatal Cases.
Topics: Adult; Baths; Cannabinoids; Chlorides; Creatinine; Dronabinol; Fatal Outcome; Female; Hot Temperatur | 2019 |
The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward.
Topics: Animals; Benzoxazines; Benzoxazoles; Cannabinoid Receptor Agonists; Cannabinoids; Conditioning, Oper | 2014 |